NCT02406014 - Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp | Biotech Hunter

Enrollment

502

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions

Actinic Keratosis (AK)

Interventions

DRUG

Ingenol Mebutate Gel, 0.015%

Ingenol mebutate gel 0.015 % (Picato®) applied on the selected treatment area. Retreatment if the treatment field is not completely cleared of AKs.

DRUG

Diclofenac sodium gel 3%

Diclofenac sodium gel 3% Solaraze® applied on the selected treatment area, twice daily for 90 days.

Trial Locations (1)

Gemain, Weber & Craninic, Schweinfurt